Semax Explained
| Image Class: | skin-invert-image |
| Width: | 250px |
| Tradename: | Semax |
| Legal Us: | Not FDA approved; unscheduled |
| Cas Number: | 80714-61-0 |
| Cas Supplemental: | 4037-01-8 |
| Unii: | I5FAL2585H |
| Atc Prefix: | N06BX |
| Pubchem: | 122178 |
| Synonyms: | L-Methionyl-L-α-glutamylhistidyl-L-phenylalanyl-L-prolylglycyl-L-proline, (Pro8,Gly9,Pro10)ACTH-(4-10), H-Met-Glu-His-Phe-Pro-Gly-Pro-OH, MEHFPGP, H-MEHFPGP-OH |
| Iupac Name: | (2S)-1-[2-<nowiki/>{[(2''S'')-1-[(2''S'')-2-<nowiki/>{[2-<nowiki/>{[(2''S'')-2-<nowiki/>{[(2''S'')-2-amino-4-methylsulfanylbutanoyl]amino}-4-carboxybutanoyl]amino}-3-(1H-imidazol-5-yl)propanoyl]amino}-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino}acetyl]pyrrolidine-2-carboxylic acid |
| C: | 37 |
| H: | 51 |
| N: | 9 |
| O: | 10 |
| S: | 1 |
| Smiles: | O=C(N[C@@H](CCC(O)=O)C(N[C@@H](CC1=CNC=N1)C(N[C@@H](CC2=CC=CC=C2)C(N3[C@@H](CCC3)C(NCC(N4[C@@H](CCC4)C(O)=O)=O)=O)=O)=O)=O)[C@H](CCSC)N |
| Chemspiderid: | 108969 |
| Stdinchi: | 1S/C37H51N9O10S/c1-57-16-13-24(38)32(50)42-25(11-12-31(48)49)33(51)43-26(18-23-19-39-21-41-23)34(52)44-27(17-22-7-3-2-4-8-22)36(54)46-15-5-9-28(46)35(53)40-20-30(47)45-14-6-10-29(45)37(55)56/h2-4,7-8,19,21,24-29H,5-6,9-18,20,38H2,1H3,(H,39,41)(H,40,53)(H,42,50)(H,43,51)(H,44,52)(H,48,49)(H,55,56)/t24-,25-,26?,27-,28-,29-/m0/s1 |
| Stdinchikey: | AFEHBIGDWIGTEH-CXFOGXNKSA-N |
Semax (Russian: СЕМАКС), an abbreviation of "seven amino acids", Russian: СЕМь АминоКиСлот) is a medication which is used in Eastern Europe for the treatment of a broad range of conditions like brain trauma but predominantly for its claimed nootropic, neuroprotective, and neurorestorative effects.[1]
The mechanism of action of Semax is unknown. It might interact with certain melanocortin receptors or inhibit enkephalinase enzymes. Chemically, Semax is a peptide and a synthetic analogue of a fragment of adrenocorticotropic hormone (ACTH).
Semax was first described in scientific literature in 1991.[2] Although used as a prescription drug in Russia, Semax has not been evaluated, approved for use, or marketed in most other countries.[3] [4] The drug is widely sold by online vendors and used as a purported nootropic (cognitive enhancer).[5]
Medical uses
Semax [6] has undergone extensive study in Russia and is on the Russian List of Vital & Essential Drugs approved by the Russian Federation government on 7 December 2011.[7] Medical uses for Semax include treatment of stroke, transient ischemic attack, memory and cognitive disorders, peptic ulcers, optic nerve disease, and to boost the immune system.[8] [9] [10] [11]
Pharmacology
Semax is a heptapeptide and synthetic analogue of a fragment of adrenocorticotropic hormone (ACTH), ACTH (4-10), of the following amino acid sequence: Met-Glu-His-Phe-Pro-Gly-Pro (in single-letter form).[12]
In animals, Semax rapidly elevates the levels and expression of brain-derived neurotrophic factor (BDNF) and its signaling receptor tropomyosin receptor kinase B (TrkB) in the hippocampus,[13] and rapidly activates serotonergic and dopaminergic brain systems.[14] [15] Accordingly, it has been found to produce antidepressant-like and anxiolytic-like effects,[16] [17] attenuate the behavioral effects of exposure to chronic stress, and potentiate the locomotor activity produced by D-amphetamine.[18] As such, it has been suggested that Semax may be effective in the treatment of depression.[19]
Though the exact mechanism of action of Semax is unclear, there is evidence that it may act through melanocortin receptors. Specifically, there is a report of Semax competitively antagonizing the action of α-melanocyte-stimulating hormone (α-MSH) at the MC4 and MC5 receptors in both in vitro and in vivo experimental conditions, indicating that it may act as an antagonist or partial agonist of these receptors. (&alpha-MSH acts as a full agonist of all five melanocortin receptors).[20] Semax did not antagonize α-MSH at the MC3 receptor, though this receptor could still be a target of the drug. As for the MC1 and MC2 receptors, they were not assayed.
In addition to actions at receptors, Semax, as well as a related peptide drug, Selank, have been found to inhibit enzymes involved in the degradation of enkephalins and other endogenous regulatory peptides (IC50 = 10μM), though the clinical significance of this property is uncertain.[21]
As a peptide, Semax has poor oral bioavailability and hence is administered parenterally as a nasal spray or subcutaneous injection.
See also
Notes and References
- Voronina TA . Cognitive Impairment and Nootropic Drugs: Mechanism of Action and Spectrum of Effects . Neurochemical Journal . 17 . 2 . 2023 . 1819-7124 . 10.1134/S1819712423020198 . 180–188. free .
- Potaman VN, Alfeeva LY, Kamensky AA, Levitzkaya NG, Nezavibatko VN . N-terminal degradation of ACTH(4-10) and its synthetic analog semax by the rat blood enzymes . Biochemical and Biophysical Research Communications . 176 . 2 . 741–746 . April 1991 . 1851003 . 10.1016/S0006-291X(05)80247-5 . 1991BBRC..176..741P .
- Web site: Home . AdisInsight . 3 September 2024.
- Web site: Semax - Search Results - PubMed . 2023-11-12 . PubMed . en.
- Jędrejko K, Catlin O, Stewart T, Anderson A, Muszyńska B, Catlin DH . Unauthorized ingredients in "nootropic" dietary supplements: A review of the history, pharmacology, prevalence, international regulations, and potential as doping agents . Drug Testing and Analysis . 15 . 8 . 803–839 . August 2023 . 37357012 . 10.1002/dta.3529 . Wiley .
- Web site: 2012 . ПЕРЕЧЕНЬ. жизненно необходимых и важнейших лекарственных препаратов на 2012 год. (Vital and Essential Drugs List, 2012) - Russian Federation . dead . https://web.archive.org/web/20150202044326/http://apps.who.int/medicinedocs/en/d/Js19766ru/ . February 2, 2015 . World Health Organization.
- Web site: ПЕРЕЧЕНЬ. жизненно необходимых и важнейших лекарственных препаратов на 2012 год. (Vital and Essential Drugs List, 2012) - Russian Federation . https://web.archive.org/web/20150202044326/http://apps.who.int/medicinedocs/en/d/Js19766ru/ . dead . February 2, 2015 . World Health Organization . 2012.
- Web site: Semax . Institute of Molecular Genetics, Russian Academy of Sciences . 6 October 2012 . 25 March 2013 . https://web.archive.org/web/20130325090400/http://old.img.ras.ru/semax1-e.htm . dead .
- Kurysheva NI, Shpak AA, Ioĭleva EE, Galanter LI, Nagornova ND, Shubina NI, Shlyshalova NN . [Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone] . Vestnik Oftalmologii . 117 . 4 . 5–8 . 2001 . 11569188 .
- Ivanikov IO, Brekhova ME, Samonina GE, Myasoedov NF, Ashmarin IP . Therapy of peptic ulcer with semax peptide . Bulletin of Experimental Biology and Medicine . 134 . 1 . 73–74 . July 2002 . 12459874 . 10.1023/A:1020621124776 . 23447014 .
- Korneev EA, Kazakova TB . Current approaches to the analysis of the effects of stress on metabolic processes in cells of the nervous and immune systems . Med. Immunology . 1999 . 1 . 1–2 . 17–22.
- Deigin VI, Poluektova EA, Beniashvili AG, Kozin SA, Poluektov YM . Development of Peptide Biopharmaceuticals in Russia . Pharmaceutics . 14 . 4 . 716 . March 2022 . 35456550 . 9030433 . 10.3390/pharmaceutics14040716 . free .
- Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, Dubynina EV, Novosadova EV, Andreeva LA, Alfeeva LY, Kamensky AA, Grivennikov IA, Myasoedov NF, Engele J . Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus . Brain Research . 1117 . 1 . 54–60 . October 2006 . 16996037 . 10.1016/j.brainres.2006.07.108 . 27592503 .
- Eremin KO, Kudrin VS, Grivennikov IA, Miasoedov NF, Rayevsky KS . Effects of Semax on dopaminergic and serotoninergic systems of the brain . Doklady Biological Sciences . 394 . 1–6 . 1–3 . 2004 . 15088389 . 10.1023/b:dobs.0000017114.24474.40 . 12955434 .
- Eremin KO, Kudrin VS, Saransaari P, Oja SS, Grivennikov IA, Myasoedov NF, Rayevsky KS . Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents . Neurochemical Research . 30 . 12 . 1493–1500 . December 2005 . 16362768 . 10.1007/s11064-005-8826-8 . 38202287 .
- Vilenskiĭ DA, Levitskaia NG, Andreeva LA, Alfeeva LI, Kamenskiĭ AA, Miasoedov NF . [Effects of chronic Semax administration on exploratory activity and emotional reaction in white rats] . ru . Rossiiskii Fiziologicheskii Zhurnal imeni I.M. Sechenova . 93 . 6 . 661–669 . June 2007 . 17850024 .
- Yatsenko KA, Glazova NY, Inozemtseva LS, Andreeva LA, Kamensky AA, Grivennikov IA, Levitskaya NG, Dolotov OV, Myasoedov NF . Heptapeptide semax attenuates the effects of chronic unpredictable stress in rats . Doklady Biological Sciences . 453 . 353–357 . November 2013 . 24385169 . 10.1134/S0012496613060161 . 9699654 .
- Volodina MA, Sebentsova EA, Glazova NY, Levitskaya NG, Andreeva LA, Manchenko DM, Kamensky AA, Myasoedov NF . Semax attenuates the influence of neonatal maternal deprivation on the behavior of adolescent white rats . Bulletin of Experimental Biology and Medicine . 152 . 5 . 560–563 . March 2012 . 22803132 . 10.1007/s10517-012-1574-2 . 1419653 .
- Pae CU . Therapeutic possibility of "Semax" for depression . CNS Spectrums . 13 . 1 . 20–21 . January 2008 . 18204410 . 10.1017/S1092852900016102 . free .
- Bertolini A . Drug-induced activation of the nervous control of inflammation: a novel possibility for the treatment of hypoxic damage . European Journal of Pharmacology . 679 . 1–3 . 1–8 . March 2012 . 22293371 . 10.1016/j.ejphar.2012.01.004 .
- Kost NV, Sokolov OI, Gabaeva MV, Grivennikov IA, Andreeva LA, Miasoedov NF, Zozulia AA . Semax and selank inhibit the enkephalin-degrading enzymes from human serum . ru . Bioorganicheskaia Khimiia . 27 . 3 . 180–183 . 2001 . 11443939 . 10.1023/A:1011373002885 . 26029820 .